Therapy challenges for NMOSD in a patient with HIV.

Engels, Daniel; Havla, Joachim; Förderreuther, Stefanie; Kümpfel, Tania

Engels, Daniel; Havla, Joachim; Förderreuther, Stefanie; Kümpfel, Tania.

Affiliation

Engels D; Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Havla J; Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Förderreuther S; Department of Neurology, University Hospital, LMU Munich, Munich, Germany.
Kümpfel T; Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.

Mult Scler ; 29(14): 1872-1875, 2023 Dec.

Article in En | MEDLINE | ID: mdl-37712413

Subject(s)

HIV Infections; Neuromyelitis Optica; Humans; Neuromyelitis Optica/complications; Neuromyelitis Optica/therapy; Neuromyelitis Optica/epidemiology; Aquaporin 4; COVID-19 Vaccines; HIV Infections/complications; Pandemics; Autoantibodies

Key words

HIV; Neuromyelitis optica (NMO); rituximab; satralizumab

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: HIV Infections / Neuromyelitis Optica Limits: Humans Language: En Journal: Mult Scler Journal subject: NEUROLOGIA Year: 2023 Type: Article Affiliation country: Germany

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google